Quoting Benedikt Westphalen, Medical Lead Precision Oncology, on X/Twitter:
“First results of CUPISCO presented at ESMO23.
Comprehensive genomic profiling, an MTB, and targeted treatments improve progression-free survival in patients with poor prognosis cancer of unknown primary over platinum CTX.
THIS IS BIG ”
Source: Benedikt Westphalen/Twitter
